11/12
07:30 am
bcax
Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Medium
Report
Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
11/11
04:01 pm
bcax
Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference
Medium
Report
Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference
11/6
06:32 am
bcax
Bicara Therapeutics Inc. (NASDAQ: BCAX) was upgraded by analysts at RODMAN&RENSHAW to a "strong-buy" rating.
Medium
Report
Bicara Therapeutics Inc. (NASDAQ: BCAX) was upgraded by analysts at RODMAN&RENSHAW to a "strong-buy" rating.
11/5
07:30 am
bcax
Bicara Therapeutics Inc. (NASDAQ: BCAX) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $48.00 price target on the stock.
Low
Report
Bicara Therapeutics Inc. (NASDAQ: BCAX) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $48.00 price target on the stock.
10/8
08:39 am
bcax
Bicara Therapeutics Inc. (NASDAQ: BCAX) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
Medium
Report
Bicara Therapeutics Inc. (NASDAQ: BCAX) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
10/8
07:32 am
bcax
Bicara Therapeutics Inc. (NASDAQ: BCAX) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $47.00 price target on the stock.
Medium
Report
Bicara Therapeutics Inc. (NASDAQ: BCAX) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $47.00 price target on the stock.
10/8
07:32 am
bcax
Bicara Therapeutics Inc. (NASDAQ: BCAX) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.
Medium
Report
Bicara Therapeutics Inc. (NASDAQ: BCAX) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.
10/8
07:32 am
bcax
Bicara Therapeutics Inc. (NASDAQ: BCAX) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $35.00 price target on the stock.
Medium
Report
Bicara Therapeutics Inc. (NASDAQ: BCAX) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $35.00 price target on the stock.
9/16
04:01 pm
bcax
Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Medium
Report
Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
9/12
09:15 pm
bcax
Bicara Therapeutics Announces Pricing of Upsized Initial Public Offering
High
Report
Bicara Therapeutics Announces Pricing of Upsized Initial Public Offering